Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I mass balance, pharmacokinetics, and absolute bioavailability study of BI 690517 in healthy male subjects
NL-OMON51347Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vicadrostat in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Mass balance recovery of [14C] radioactivity in urine and feces after oral administration and AUC0-* of [14C] BI 690517 (intravenous) and BI 690517 (oral). Started Sep 2022; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON51347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51347.